Tariquidar

Tariquidar
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide;
CAS Number	206873-63-4 ;
PubChem CID	148201;
ChemSpider	130650 ;
UNII	J58862DTVD;
ChEMBL	ChEMBL348475 ;
CompTox Dashboard (EPA)	DTXSID10174746 ;
Chemical and physical data
Formula	C38H38N4O6
Molar mass	646.744 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC;
	InChI InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43) ; Key:LGGHDPFKSSRQNS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tariquidar (INN/USAN) is a potent P-glycoprotein inhibitor and a substrate of breast cancer protein (BCRP/ABCG2)^[1] undergoing research as an adjuvant against multi-drug resistance in cancer.^[2]

Tariquidar progressed to phase III clinical trials in combination with vinorelbine in an effort to enhance the efficacy of this chemotherapeutic agent. However, several of these trials were terminated early due to adverse effects, and further development of Tariquidar was subsequently halted.^[3]

References

↑ Weidner LD, Fung KL, Kannan P, Moen JK, Kumar JS, Mulder J, et al. (February 2016). "Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 44 (2): 275–282. doi:10.1124/dmd.115.067785. PMC 4746486. PMID 26658428.
↑ Fox E, Bates SE (April 2007). "Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor". Expert Review of Anticancer Therapy. 7 (4): 447–459. doi:10.1586/14737140.7.4.447. PMID 17428165.
↑ Modok S, Mellor HR, Callaghan R (August 2006). "Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer". Current Opinion in Pharmacology. 6 (4): 350–354. doi:10.1016/j.coph.2006.01.009. PMID 16690355.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

[1] Weidner LD, Fung KL, Kannan P, Moen JK, Kumar JS, Mulder J, et al. (February 2016). "Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 44 (2): 275–282. doi:10.1124/dmd.115.067785. PMC 4746486. PMID 26658428.

[Fox_2007-2] Fox E, Bates SE (April 2007). "Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor". Expert Review of Anticancer Therapy. 7 (4): 447–459. doi:10.1586/14737140.7.4.447. PMID 17428165.

[pmid16690355-3] Modok S, Mellor HR, Callaghan R (August 2006). "Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer". Current Opinion in Pharmacology. 6 (4): 350–354. doi:10.1016/j.coph.2006.01.009. PMID 16690355.

[1]

[2]

[3]

This page was redesigned at the edge.

A page that knows where it met you.

Tariquidar

References